1. Home
  2. CLLS vs MPA Comparison

CLLS vs MPA Comparison

Compare CLLS & MPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CLLS
  • MPA
  • Stock Information
  • Founded
  • CLLS 1999
  • MPA 1992
  • Country
  • CLLS France
  • MPA United States
  • Employees
  • CLLS N/A
  • MPA N/A
  • Industry
  • CLLS Biotechnology: Pharmaceutical Preparations
  • MPA Finance Companies
  • Sector
  • CLLS Health Care
  • MPA Finance
  • Exchange
  • CLLS Nasdaq
  • MPA Nasdaq
  • Market Cap
  • CLLS 148.1M
  • MPA 150.5M
  • IPO Year
  • CLLS 2007
  • MPA N/A
  • Fundamental
  • Price
  • CLLS $1.32
  • MPA $11.24
  • Analyst Decision
  • CLLS Buy
  • MPA
  • Analyst Count
  • CLLS 3
  • MPA 0
  • Target Price
  • CLLS $7.00
  • MPA N/A
  • AVG Volume (30 Days)
  • CLLS 839.3K
  • MPA 25.2K
  • Earning Date
  • CLLS 03-13-2025
  • MPA 01-01-0001
  • Dividend Yield
  • CLLS N/A
  • MPA 3.83%
  • EPS Growth
  • CLLS N/A
  • MPA N/A
  • EPS
  • CLLS N/A
  • MPA N/A
  • Revenue
  • CLLS $49,217,000.00
  • MPA N/A
  • Revenue This Year
  • CLLS $1.26
  • MPA N/A
  • Revenue Next Year
  • CLLS N/A
  • MPA N/A
  • P/E Ratio
  • CLLS N/A
  • MPA N/A
  • Revenue Growth
  • CLLS 435.38
  • MPA N/A
  • 52 Week Low
  • CLLS $1.14
  • MPA $9.87
  • 52 Week High
  • CLLS $3.38
  • MPA $12.21
  • Technical
  • Relative Strength Index (RSI)
  • CLLS 49.18
  • MPA 39.38
  • Support Level
  • CLLS $1.16
  • MPA $11.11
  • Resistance Level
  • CLLS $1.35
  • MPA $11.39
  • Average True Range (ATR)
  • CLLS 0.07
  • MPA 0.09
  • MACD
  • CLLS 0.01
  • MPA -0.00
  • Stochastic Oscillator
  • CLLS 69.23
  • MPA 33.33

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.

About MPA Blackrock MuniYield Pennsylvania Quality Fund

Blackrock Muniyield Pennsylvania Quality Fund is a closed-end fund with investment objective is to provide shareholders with current income exempt from U.S. federal and Pennsylvania income taxes.

Share on Social Networks: